Thyrocare Technologies Ltd
Thyrocare Technologies is engaged in the business of healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.
- Market Cap ₹ 6,685 Cr.
- Current Price ₹ 420
- High / Low ₹ 538 / 219
- Stock P/E 47.1
- Book Value ₹ 33.6
- Dividend Yield 1.67 %
- ROCE 24.8 %
- ROE 16.2 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 135%
- Company's working capital requirements have reduced from 17.1 days to 12.8 days
Cons
- Stock is trading at 12.5 times its book value
- Promoter holding has decreased over last quarter: -10.1%
- The company has delivered a poor sales growth of 9.62% over past five years.
- Company has a low return on equity of 13.9% over last 3 years.
- Promoters have pledged 100% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 183 | 241 | 304 | 356 | 403 | 434 | 495 | 589 | 527 | 572 | 687 | 792 | |
| 110 | 147 | 189 | 212 | 249 | 261 | 323 | 353 | 403 | 432 | 498 | 548 | |
| Operating Profit | 73 | 94 | 115 | 145 | 154 | 174 | 171 | 236 | 123 | 140 | 190 | 244 |
| OPM % | 40% | 39% | 38% | 41% | 38% | 40% | 35% | 40% | 23% | 24% | 28% | 31% |
| 8 | 7 | -15 | 21 | 11 | 1 | 12 | 29 | 9 | 9 | 15 | 12 | |
| Interest | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 3 | 5 | 6 | 4 | 2 |
| Depreciation | 13 | 18 | 18 | 20 | 26 | 32 | 30 | 34 | 39 | 47 | 55 | 58 |
| Profit before tax | 68 | 82 | 82 | 145 | 138 | 140 | 152 | 228 | 89 | 96 | 145 | 196 |
| Tax % | 35% | 37% | 48% | 36% | 38% | 37% | 26% | 23% | 27% | 28% | 38% | |
| 44 | 52 | 43 | 93 | 85 | 88 | 113 | 176 | 64 | 69 | 91 | 136 | |
| EPS in Rs | 2.98 | 3.21 | 2.66 | 5.79 | 5.38 | 5.58 | 7.13 | 11.10 | 4.06 | 4.45 | 5.76 | 8.65 |
| Dividend Payout % | 171% | 104% | 125% | 58% | 124% | 30% | 117% | 45% | 148% | 135% | 122% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 10% |
| 3 Years: | 5% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | -1% |
| 3 Years: | -18% |
| TTM: | 62% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 33% |
| 1 Year: | 58% |
| Return on Equity | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 20% |
| 3 Years: | 14% |
| Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 51 | 54 | 54 | 54 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 |
| Reserves | 226 | 312 | 354 | 390 | 382 | 314 | 374 | 474 | 481 | 474 | 494 | 481 |
| 0 | 0 | 0 | 0 | 2 | 12 | 8 | 21 | 23 | 42 | 25 | 25 | |
| 53 | 44 | 30 | 36 | 37 | 90 | 106 | 60 | 74 | 75 | 121 | 121 | |
| Total Liabilities | 329 | 410 | 438 | 479 | 475 | 469 | 541 | 607 | 632 | 644 | 693 | 680 |
| 196 | 259 | 259 | 299 | 294 | 269 | 253 | 285 | 294 | 306 | 297 | 301 | |
| CWIP | 6 | 1 | 17 | 0 | 1 | 5 | 8 | 3 | 2 | 3 | 14 | 3 |
| Investments | 86 | 93 | 104 | 120 | 95 | 90 | 126 | 146 | 144 | 162 | 162 | 146 |
| 42 | 56 | 58 | 60 | 84 | 105 | 154 | 173 | 192 | 173 | 220 | 230 | |
| Total Assets | 329 | 410 | 438 | 479 | 475 | 469 | 541 | 607 | 632 | 644 | 693 | 680 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 34 | 68 | 90 | 107 | 100 | 168 | 115 | 113 | 129 | 168 | 191 | |
| -18 | -18 | -42 | -43 | -12 | 1 | -49 | -24 | -39 | -91 | -53 | |
| -23 | -45 | -49 | -64 | -94 | -165 | -62 | -89 | -86 | -85 | -130 | |
| Net Cash Flow | -6 | 5 | -0 | -0 | -5 | 4 | 4 | 0 | 4 | -8 | 8 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 10 | 11 | 8 | 10 | 11 | 14 | 33 | 58 | 59 | 28 | 39 |
| Inventory Days | 48 | 56 | 65 | 66 | 60 | 64 | 52 | 53 | 62 | 104 | 89 |
| Days Payable | 5 | 10 | 6 | 25 | 25 | 68 | 56 | 36 | 54 | 88 | 146 |
| Cash Conversion Cycle | 53 | 57 | 67 | 50 | 46 | 10 | 29 | 75 | 67 | 44 | -18 |
| Working Capital Days | 28 | 2 | 19 | 10 | 28 | -8 | 19 | 41 | 31 | 7 | 13 |
| ROCE % | 24% | 28% | 33% | 30% | 35% | 36% | 42% | 17% | 18% | 25% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1d - Newspaper Publications on Unaudited Financial results for the quarter and nine months ended on December 31, 2025
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
2d - Audio of earnings call (Jan 28, 2026) for quarter and nine months ended Dec 31, 2025 available online.
-
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
2d - Board approved PIT Code amendment on Jan 28, 2026; amended code published online.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
2d - Investor Presentation on the unaudited financial results for the quarter and nine months ended December 31, 2025.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2d - Q3 FY26 consolidated revenue ₹195.53Cr, PAT ₹27.91Cr; 49.6mn tests; Madhuri Dixit onboarded as ambassador.
Annual reports
Concalls
-
Jan 2026TranscriptAI SummaryPPT
-
Oct 2025Transcript PPT
-
Jul 2025Transcript PPT REC
-
Apr 2025Transcript PPT REC
-
Jan 2025Transcript PPT
-
Oct 2024Transcript PPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
-
Aug 2021TranscriptAI SummaryPPT
-
May 2021TranscriptAI SummaryPPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Jul 2020TranscriptAI SummaryPPT
-
May 2020TranscriptAI SummaryPPT
-
Feb 2020TranscriptAI SummaryPPT
-
Nov 2019TranscriptAI SummaryPPT
-
Aug 2019TranscriptAI SummaryPPT
-
Jun 2019TranscriptPPT
-
May 2019TranscriptAI SummaryPPT
-
Feb 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018Transcript PPT
-
Feb 2018Transcript PPT
-
Dec 2017Transcript PPT
Business Segments
1) Diagnostic Testing Services (92% in FY25 vs 94% in FY22): [1] [2] The company is one of the leading Pan-India diagnostic chains, offering a range of tests focused on early disease detection and health management. It provides 929 tests and 288 profiles, including 43 wellness packages under the “Aarogyam” brand. It processes 3 Bn investigations annually and can process 10 Bn annually. [3] [4]